These 4 Companies Are Trending The Past Week

Dear Reader, According to our research, there are a few trending companies that have recently received buy ratings and showing a combination of positive investor sentiment, news headlines and blog buzz. With that said, we are not recommending buying these names but we are adding them to our stock watchlist. We will continue to monitor companies to see if the momentum continues. --------------------------------------------------------------- Sponsor [Mass Shooting Epidemic Creates Bombing Threat Detection Industry]( a week goes by without hearing about a mass shooting. Schools, subways, churches, grocery stores... Is any place safe? Fortunately, new tech that can rapidly detect metal & non-metal threats has been designed by top U.S. engineers. Right now, it's being beta-tested in various industries and will soon hit the commercial market. [See Who Could Benefit From This Cutting-Edge Investment Opportunity]( --------------------------------------------------------------- [Denali Therapeutics, DNLI]( Summary: Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. Jessica Fye analyst at J.P. Morgan reiterates coverage on [Denali Therapeutics (DNLI)]( with a Buy rating and has set a price target of $ 65. [TipRanks.com]( reports that [Denali Therapeutics]( has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $58.78. In addition, TradingView issued a n/a (possibly response change) rating for [DNLI]( over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. [For the chart and additional details on DNLI, please click here >>]( --------------------------------------------------------------- [Madrigal Pharmaceuticals, MDGL]( Summary: Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-' agonist which are in pre-clinical trial stage. Jonathan Wolleben analyst at JMP Securities reiterates coverage on [Madrigal Pharmaceuticals (MDGL)]( with a Buy rating and has set a price target of $ 390. [TipRanks.com]( reports that [Madrigal Pharmaceuticals]( has 13 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $303.00. In addition, TradingView issued a Buy rating for [MDGL]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. [For the chart and additional details on MDGL, please click here >>]( --------------------------------------------------------------- Sponsor [Banking Regulators Warns Americans to Pay Attention to Friday, January 20th]( [Get the Full Story Here]( --------------------------------------------------------------- [Osisko Gold Royalties, OR]( Summary: Osisko Gold Ltd is a mining company which is engaged in exploration and mining for gold and other precious metals. Osisko Gold Ltd is headquartered in Montreal, Canada. Carey MacRury analyst at Canaccord Genuity reiterates coverage on [Osisko Gold Royalties (OR)]( with a Buy rating and has set a price target of $ 17.1. [TipRanks.com]( reports that [Osisko Gold Royalties]( has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $16.17. In addition, TradingView issued a Strong Buy rating for [OR]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. [For the chart and additional details on OR, please click here >>]( --------------------------------------------------------------- [Sigma Lithium, SGML]( Summary: Sigma Lithium Corporation is involved in producing battery-grade lithium. Sigma Lithium Corporation is based in VANCOUVER, BC. Joel Jackson analyst at BMO Capital reiterates coverage on [Sigma Lithium (SGML)]( with a Buy rating and has set a price target of $ 40. [TipRanks.com]( reports that [Sigma Lithium]( has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $45.03. In addition, TradingView issued a Neutral rating for [SGML]( over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Neutral short-term outlook. [For the chart and additional details on SGML, please click here >>]( --------------------------------------------------------------- Sponsor ["I only trade ONE stock & I NEVER worry about..."]( name of the ONE stock (ticker symbol and all) that has helped over 170,000 people discover how to gain their financial freedom... [Learn More.]( --------------------------------------------------------------- Remember, securities are volatile, so please do your own research. One resource you need to consider using [Tipranks.com]( where as a premium member you get access to all buy ratings, price targets and insider trading signals. [Get more from TipRanks.com here >>]( Thanks for reading! The Editor, [wallstreetanalystpress.com]( --------------------------------------------------------------- Sponsor [New Documentary: The Two Men Destroying America]( This is causing a lot of controversy… It’s a new documentary called [The Two Men Destroying America.]( And a lot of powerful people would rather this exposé never saw the light of day. Chances are, they’ll attempt to have it scrubbed from existence. That’s because it tells the true (and terrifying) story of how two men from New York have engineered a reset of not just your personal wealth, but the entire US economic system. [Click play to watch The Two Men Destroying America]( --------------------------------------------------------------- [To Cancel Your Free Subscription, click here.]( WallStreetAnalystPress.com Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to WallStreetAnalystPress. WallStreetAnalystPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy Unit 407 | Mt. Mourne | North Carolina | 28123 [UNSUBSCRIBE](